Paying For Gene Therapy: Medicaid Will Be ‘Canary In Coal Mine’

Harvard Pilgrim's Michael Sherman and Cigna's Steve Miller advise gene therapy developers to consider the burden of high cost treatments on Medicaid programs when setting list prices.